Discussion to focus on Tablo® Hemodialysis System and Home Dialysis
SAN JOSE, Calif.–(BUSINESS WIRE)–Outset Medical, Inc. (Nasdaq: OM) (“Outset”), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis, today announced that it will host a virtual patient and physician webinar on its Tablo® Hemodialysis System for use in home dialysis on Wednesday, June 1, 2022 at 1:00pm PT / 4:00pm ET.
The live webinar, intended for investment professionals, will feature a panel discussion moderated by Michael Aragon, MD, Outset’s Chief Medical Officer, between Tablo home dialysis patients and Varshi Broumand, MD, MHA, FACP, FASN, Dialysis Medical Director at CHRISTUS Santa Rosa Health System and nephrologist at South Texas Renal Care Group. The discussion will focus on the patient care journey to home dialysis and each patient’s experience dialyzing at home with Tablo.
A live question and answer session will follow. To register for the event, please click here.
A live and archived webcast of the webinar will be available on the “Investors” section of the Outset website at https://investors.outsetmedical.com/.
About Outset Medical, Inc.
Outset is a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis. The Tablo Hemodialysis System, FDA cleared for use from the hospital to the home, represents a significant technological advancement that transforms the dialysis experience for patients and operationally simplifies it for providers. Tablo serves as a single enterprise solution that can be utilized across the continuum of care, allowing dialysis to be delivered anytime, anywhere and by anyone. The integration of water purification and on-demand dialysate production enables Tablo to serve as a dialysis clinic on wheels, with 2-way wireless data transmission and a proprietary data analytics platform powering a new holistic approach to dialysis care. Tablo is a registered trademark of Outset Medical, Inc.
Vice President, Investor Relations